Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.

摘要: Cisapride is an orally administered prokinetic agent which facilitates or restores motility throughout the length of gastrointestinal tract. It a substituted piperidinyl benzamide, chemically related to metoclopramide, but unlike cisapride largely devoid central depressant antidopaminergic effects. In placebo-controlled trials, improved healing rates and symptoms in both adults children with reflux oesophagitis. Maintenance therapy at half dose effective reducing incidence relapse. Symptoms are also alleviated patients functional dyspepsia, gastric emptying most gastroparesis, effect sustained during long term administration. However, efficacy end-stage gastroparesis remains less clear. increases stool frequency chronic constipation, limited data suggest that drug may be beneficial treating intestinal pseudo-obstruction irritable bowel syndrome. demonstrated comparable superior was least as cimetidine ranitidine disease. has shown equal domperidone, metoclopramide ranitidine, small comparative trials conducted date. Adverse effects receiving generally transient mild, abdominal cramping, borborygmi, diarrhoea loose stools frequently reported. Central nervous system adverse rare. Thus, its favourable tolerability profile variety disorders, position valuable management disorders strengthening. larger well-controlled other agents necessary before relative can categorically defined.